DOES IMPAIRMENT OF ENERGY-METABOLISM RESULT IN EXCITOTOXIC NEURONAL DEATH IN NEURODEGENERATIVE ILLNESSES

被引:912
作者
BEAL, MF [1 ]
机构
[1] HARVARD UNIV,SCH MED,BOSTON,MA 02115
关键词
D O I
10.1002/ana.410310202
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The etiology of nerve cell death in neuronal degenerative diseases is unknown, but it has been hypothesized that excitotoxic mechanisms may play a role. Such mechanisms may play a role in diseases such as Huntington's disease, Parkinson's disease, amyotrophic lateral sclerosis, and Alzheimer's disease. In these illnesses, the slowly evolving neuronal death is unlikely to be due to a sudden release of glutamate, such as occurs in ischemia. One possibility, however, is that a defect in mitochondrial energy metabolism could secondarily lead to slow excitotoxic neuronal death, by making neurons more vulnerable to endogenous glutamate. With reduced oxidative metabolism and partial cell membrane depolarization, voltage-dependent N-methyl-D-aspartate (NMDA) receptor ion channels would be more easily activated. In addition, several other processes involved in buffering intracellular calcium may be impaired. Recent studies in experimental animals showed that mitochondrial toxins can result in a pattern of neuronal degeneration closely resembling that seen in Huntington's disease, which can be blocked with NMDA antagonists. NMDA antagonists also block neuronal degeneration induced by 1-methyl-4-phenylpyridium, which has been implicated in experimental models of Parkinson's disease. The delayed onset of neurodegenerative illnesses could be related to the progressive impairment of mitochondrial oxidative phosphorylation, which accompanies normal aging. If defective mitochondrial energy metabolism plays a role in cell death in neurodegenerative disorders, potential therapeutic strategies would be to use excitatory amino acid antagonists or agents to bypass bioenergetic defects.
引用
收藏
页码:119 / 130
页数:12
相关论文
共 174 条
[21]   ISCHEMIC DAMAGE IN THE STRIATUM OF ADULT GERBILS - RELATIVE SPARING OF SOMATOSTATINERGIC AND CHOLINERGIC INTERNEURONS CONTRASTS WITH LOSS OF EFFERENT NEURONS [J].
CHESSELET, MF ;
GONZALES, C ;
LIN, CS ;
POLSKY, K ;
JIN, BK .
EXPERIMENTAL NEUROLOGY, 1990, 110 (02) :209-218
[22]   EFFECT OF NMDA-INSENSITIVE AND STRYCHNINE-INSENSITIVE GLYCINE SITE ANTAGONISTS ON NMDA-MEDIATED CONVULSIONS AND LEARNING [J].
CHIAMULERA, C ;
COSTA, S ;
REGGIANI, A .
PSYCHOPHARMACOLOGY, 1990, 102 (04) :551-552
[23]  
CHOI DW, 1990, CEREBROVAS BRAIN MET, V2, P105
[24]   GLUTAMATE NEUROTOXICITY AND DISEASES OF THE NERVOUS-SYSTEM [J].
CHOI, DW .
NEURON, 1988, 1 (08) :623-634
[26]   LESION OF STRIATAL NEURONS WITH KAINIC ACID PROVIDES A MODEL FOR HUNTINGTONS-CHOREA [J].
COYLE, JT ;
SCHWARCZ, R .
NATURE, 1976, 263 (5574) :244-246
[27]   LOWERED CEREBRAL GLUCOSE-UTILIZATION IN AMYOTROPHIC-LATERAL-SCLEROSIS [J].
DALAKAS, MC ;
HATAZAWA, J ;
BROOKS, RA ;
DICHIRO, G .
ANNALS OF NEUROLOGY, 1987, 22 (05) :580-586
[28]   NO EVIDENCE FOR PRESERVATION OF SOMATOSTATIN-CONTAINING NEURONS AFTER INTRASTRIATAL INJECTIONS OF QUINOLINIC ACID [J].
DAVIES, SW ;
ROBERTS, PJ .
NATURE, 1987, 327 (6120) :326-329
[29]   SURVIVAL OF BASAL GANGLIA NEUROPEPTIDE Y-SOMATOSTATIN NEURONS IN HUNTINGTONS-DISEASE [J].
DAWBARN, D ;
DEQUIDT, ME ;
EMSON, PC .
BRAIN RESEARCH, 1985, 340 (02) :251-260
[30]  
DECKEL AW, 1983, EUR J PHARMACOL, V93, P287